# SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

> **NCT03919656** · PHASE4 · COMPLETED · sponsor: **Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud** · enrollment: 60 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin 10 mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03919656
- **Lead sponsor:** Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-12
- **Primary completion:** 2024-01-12
- **Final completion:** 2024-05-23
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03919656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03919656, "SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03919656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*